SciSparc and Clearmind’s New Patent Targets Binge Behavior Disorders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd. ( (SPRC) ) has shared an update.
On October 20, 2025, SciSparc Ltd. announced a collaboration with Clearmind Medicine Inc. that resulted in the publication of a U.S. patent application for a novel combination therapy targeting binge behavior disorders. This therapy combines MEAI and N-Acylethanolamines, leveraging psychedelic and anti-inflammatory properties to address disorders like excessive alcohol consumption and eating disorders. The collaboration aims to offer a breakthrough in treating substance use and behavioral addictions, potentially impacting the company’s market positioning in the pharmaceutical industry.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. Additionally, SciSparc has a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 4,672,611
Technical Sentiment Signal: Sell
Current Market Cap: $6.2M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.
